Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Edward Cha | Researchclopedia

Back to researchers

Edward Cha

Kaiser Permanente South San Francisco Medical Center ORCID

88

Works

3,375

Citations

28

h-index

43

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Colorectal Cancer Treatments and Studies

Affiliations

Ulsan College2007–2007

Roche (Switzerland)2025–2025

Memorial Sloan Kettering Cancer Center2020–2020

The University of Texas MD Anderson Cancer Center2023–2024

City College of San Francisco2014–2014

Top Works

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin,Minshan Chen,et al.

2023432 citations

Immune Cell Function and Interaction

CAR-T cell therapy research

Immune Response in Stat2 Knockout Mice

Christopher Y. Park,Suzanne Li,et al.

2000405 citations

Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

Edward Cha,Mark Klinger,et al.

2014379 citations

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger,Hussein A. Tawbi,et al.

2020265 citations

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Ryan J. Sullivan,Omid Hamid,et al.

2019235 citations

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Matthew D. Hellmann,T. W. Kim,et al.

2019188 citations

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

Johanna C. Bendell,Tae Won Kim,et al.

2016158 citations

LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

Adam C. Yopp,M. Kudo,et al.

202478 citations

A Blueprint to Advance Colorectal Cancer Immunotherapies

Dung T. Le,Vanessa M. Hubbard-Lucey,et al.

201771 citations